Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 3;49(1):53-67.
doi: 10.1093/schbul/sbac148.

Clozapine Therapy and COVID-19: A Systematic Review of the Prevalence Rates, Health Outcomes, Hematological Markers, and Patient Perspectives

Grace Giles  1 , Sunny Varghese  1 , Gordon Shymko  1 , Thinh Nguyen  1   2 , Flavie Waters  2   3   4
Affiliations

Clozapine Therapy and COVID-19: A Systematic Review of the Prevalence Rates, Health Outcomes, Hematological Markers, and Patient Perspectives

Grace Giles et al. Schizophr Bull. .

Abstract

Background/objectives: There have been concerns that clozapine treatment may undermine the capacity of the body to fight infection and increase the vulnerability to contracting COVID-19. This review of recent cohort studies investigated (1) whether people with a severe psychiatric disorder are at increased risk of COVID-19 and complications, (2) the immunological response of clozapine-users who contract COVID-19, and (3) patients' perspectives on COVID-19 and the pandemic response.

Methods: A systematic search of EMBASE, Medline, Pubmed, and PsycINFO databases using PRISMA guidelines using "COVID-19", "clozapine", and "vaccination" terms.

Results: 18 studies (out of 330 identified) met all criteria (N = 119 054 including 8045 on clozapine). There was no strong evidence that clozapine users may be at increased risk of contracting COVID-19 or developing complications after adjusting for medical comorbidities. Hematological studies showed temporary reductions in neutrophils in COVID-19-positive patients and vaccination suggesting a clozapine effect in defence against infection. Vaccination studies did not report major adverse effects. Increased plasma levels of clozapine and neutropenia however point to COVID-19-related interference of clozapine metabolism. Patient surveys reported limited impact on mental health and positive attitudes regarding pandemic response.

Conclusion: This review did not find compelling evidence that the immune system of clozapine users put them at risk of COVID-19 and further complications. Evidence of drug-infection interactions however points to the importance of adhering to consensus guidelines about clozapine therapy during the pandemic. More evidence using longitudinal designs is required to examine the longer-term effects of COVID-19 and vaccination in this vulnerable population.

Keywords: COVID-19; clozapine; coronavirus; schizophrenia.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flowchart of systematic literature review.
Fig. 2.
Fig. 2.
Recommendations regarding COVID-19 and patients on clozapine therapy.
See this image and copyright information in PMC

References

    1. Correll CU, Howes OD.. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021;82(5):07. doi: 10.4088/JCP.MY20096AH1C. - DOI - PubMed
    1. Swartz M, Stroup T, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv. 2008;59(5):500–506. doi: 10.1176/ps.2008.59.5.500. - DOI - PMC - PubMed
    1. Jakobsen MI, Storebø OJ, Austin SF, Nielsen J, Simonsen E.. Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol. BMJ Open. 2021;11(10):e054308. doi: 10.1136/bmjopen-2021-054308. - DOI - PMC - PubMed
    1. Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA.. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(4):296–309. doi: 10.1111/acps.12700. - DOI - PubMed
    1. Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174(10):990–998. doi: 10.1176/appi.ajp.2017.16091097. - DOI - PubMed

Publication types